Access

Correspondence

Nature Medicine 15, 1110–1112 (1 October 2009) | doi:10.1038/nm1009-1110

CCL3L1 and HIV/AIDS susceptibility

Thomas J Urban , Amy C Weintrob , Jacques Fellay , Sara Colombo , Kevin V Shianna , Curtis Gumbs , Margalida Rotger , Kimberly Pelak , Kristen K Dang , Roger Detels , Jeremy J Martinson , Stephen J O'Brien , Norman L Letvin , Andrew J McMichael , Barton F Haynes , Mary Carrington , Amalio Telenti , Nelson L Michael & David B Goldstein

To the Editor: We read with interest the recent article in Nature Medicine describing the influence of variation in CCL3L1 copy number and CCR5 genotype on immune recovery during highly active antiretroviral therapy (HAART) in HIV-1–infected individuals. The chemotactic cytokine CCL3L1 (encoding the macrophage inflammatory protein-1αP (MIP-1αP) protein) is a potent ligand for the HIV-1 co-receptor CCR5, which is essential for viral entry into human host cells.